Efficiency and its determinants in pharmaceutical industries: ownership, R&D and scale economy

被引:11
|
作者
You, Taewoo [1 ]
Chen, Xiaoying [3 ]
Holder, Mark E. [2 ]
机构
[1] Myongji Coll, Dept Business, Seoul 120776, South Korea
[2] Kent State Univ, Coll Business Adm, Dept Finance, Kent, OH 44242 USA
[3] Calif State Univ Long Beach, Coll Business Adm, Dept Finance, Long Beach, CA 90840 USA
关键词
INSTITUTIONAL INVESTORS; PERFORMANCE; MODELS; PRODUCTIVITY; ORGANIZATION; TECHNOLOGY; INVESTMENT; INFERENCE; ACTIVISM; BEHAVIOR;
D O I
10.1080/00036840701765445
中图分类号
F [经济];
学科分类号
02 ;
摘要
The purpose of this article is to measure the efficiency of pharmaceutical firms and identify their determinants using Korean and American samples from 1992 to 2004. We document some stylized facts in the patterns and sources of efficiency change in Korean and American pharmaceutical firms. The evidence shows that ownership structure can substantially influence the efficiency of pharmaceutical firms. Especially, institutional ownership rate affects corporate efficiencies negatively, corroborating the myopic institutional investor hypothesis. The hypothesis is supported by both Korean and American samples. However, we find evidence that foreign ownership in Korea promotes efficiency of pharmaceutical firms. It is shown that R&D intensity is positively related to contemporaneous largest ownership rate and prior foreign ownership rate in Korean pharmaceutical firms. In contrast, little evidence is found on the relationship between ownership structure and R&D intensity in the American pharmaceutical industry. These empirical results are robust even after we check the causal links among efficiency, R&D and ownership.
引用
收藏
页码:2217 / 2241
页数:25
相关论文
共 50 条
  • [31] The productivity crisis in pharmaceutical R&D
    Fabio Pammolli
    Laura Magazzini
    Massimo Riccaboni
    [J]. Nature Reviews Drug Discovery, 2011, 10 : 428 - 438
  • [32] The Effect of Price on Pharmaceutical R&D
    Civan, Abdulkadir
    Maloney, Michael T.
    [J]. B E JOURNAL OF ECONOMIC ANALYSIS & POLICY, 2009, 9 (01):
  • [33] Pharmaceutical R&D goes East
    Floether, Frank U.
    [J]. CHIMICA OGGI-CHEMISTRY TODAY, 2011, 29 (04) : 16 - 18
  • [34] The productivity crisis in pharmaceutical R&D
    Pammolli, Fabio
    Magazzini, Laura
    Riccaboni, Massimo
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (06) : 428 - 438
  • [35] Systems biology in pharmaceutical R&D
    Oresic, Matej
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 34 (01) : S23 - S23
  • [36] R&D portfolios and pharmaceutical licensing
    Nishimura, Junichi
    Okada, Yosuke
    [J]. RESEARCH POLICY, 2014, 43 (07) : 1250 - 1263
  • [37] Reviving pharmaceutical R&D with translational science, regulatory efficiency and innovative models
    Zhang, Tianyi
    Weng, Naidong
    Lee, Mike
    [J]. BIOANALYSIS, 2013, 5 (20) : 2463 - 2467
  • [38] R&D efficiency of leading pharmaceutical companies - A 20-year analysis
    Schuhmacher, Alexander
    Wilisch, Lucas
    Kuss, Michael
    Kandelbauer, Andreas
    Hinder, Markus
    Gassmann, Oliver
    [J]. DRUG DISCOVERY TODAY, 2021, 26 (08) : 1784 - 1789
  • [39] R&D in services industries and the EU-US R&D investment gap
    Duchene, Vincent
    Lykogianni, Elissavet
    Verbeek, Arnold
    [J]. SCIENCE AND PUBLIC POLICY, 2010, 37 (06) : 443 - 453
  • [40] Ownership and the cyclicality of firms’ R&D investment
    Pilar Beneito
    María Engracia Rochina-Barrachina
    Amparo Sanchis-Llopis
    [J]. International Entrepreneurship and Management Journal, 2015, 11 : 343 - 359